

HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

European Network of Excellence for Big Data in Hematology,
consisting of 53 partners from 11 countries.



HARMONY Platform: using Big Data to fight blood cancers

María Abáigar Alvarado¹, Renate Schulze-Rath², Ana Eugenia Rodríguez-Vicente¹, Santiago Moralejo-del-Arco¹, Aliko Taylor¹, Lars Bullinger⁵

¹Group of Molecular Genetics in Oncohematology - Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Center - University of Salamanca (USAL-CSIC), Spain; ²Bayer, Germany; ³Institute of Biomedical Research of Salamanca (IBSAL), Spain; ⁴Takeda, United Kingdom; ⁵Charité – Universitätsmedizin Berlin, Germany

22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

Big Data for Better Outcomes



Biggest IMI project in BD4BO for Blood Cancers



High quality
Platform



Outcomes
harmonization




Translating **omics data**
into clinical practice



Speed up drug
development & access
to novel therapies

HARMONY

HARMONY: from data to patients





HARMONY platform is set up & running

Leukemia

Myeloma

Lymphoma

 10 YEARS OF BREAKTHROUGHS
A HEALTHIER FUTURE

 **P - 45**
HARMONY
Harmonize Alliance for Hematologic Malignancies
Optimize against Hematologic Malignancies

Prognostic factors/outcome of Multiple Myeloma Patients enrolled in European clinical trials after long-term follow-up
Pilot project of the HARMONY Alliance Multiple Myeloma Community

HARMONY: Enabling Better and Faster Treatment for Patients with Blood Cancer.

Facts & Figures

- Start Date: 01/01/2017 | End Date: 31/12/2021
- Contributions: IMI Funding € 20 200 000
- EFPIA in kind € 19 084 265 | Other € 451 352
- Total Cost: € 39 745 617

www.harmony-alliance.eu | @HarmonyNetEU

Challenge

HARMONY focuses on Hematologic Malignancies, cancers with unmet clinical needs such as Multiple Myeloma (MM). HARMONY has developed a data platform that will register outcome measures that are relevant to different groups of stakeholders, such as physicians, patients, data scientists, drug developers, policy makers and regulators. A better definition of patients' prognosis has only partially guided therapeutic choices and influenced the outcome of high risk patients that still remains unsatisfactory. This patients' population represents an unmet clinical need even in the novel agent era.

Approach & Methodology

MM-specific pilot project

European cooperative groups are working together to provide an extended follow-up of the original trials included in the R-ISS project adding other relevant datasets with mature data from clinical trials enrolling NDMM patients treated with novel agents.


Revised-ISS

The clinical outcome of MM patients treated with novel agents and the impact of treatment approaches.

Envisioned results

- R-ISS (Revised-International Staging System) validation after an extended follow-up and comparison with other prognostic factors.
- Outcome definition of patients with low and high-risk features treated with different novel agents and treatment approaches.

Ongoing & upcoming studies



HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology



This material is developed by the HARMONY Alliance

Disclaimer

This presentation is of scientific nature and has been produced by the HARMONY Alliance.

The HARMONY Alliance makes no warranties or representations of any kind as to the content's accuracy, currency or completeness, neither the Alliance nor any party involved in creating, producing or delivering this document shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this document, or any errors or omissions in the content thereof. This material may not be used for commercial purposes.

Remixing is not permitted except for private use.

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under HARMONY Grant Agreement n°116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

www.imi.europa.eu



@IMI_JU